XXII: מחיר רכישת החברה 22nd Century Group

22nd Century Group (XXII) is developing low-nicotine tobacco production, monetizing biotech patents through seed licensing. The genetics team is creating innovative varieties to improve human health. This price chart reflects that the Enterprise Value is -4.24. The company's monopoly position is secured by FDA approval and unique bioengineering developments, which create a powerful moat against competitors.

Investors utilize this metric as an objective business acquisition cost that accounts for the combination of equity and net debt. The current value of -4.24, represented via the market valuation of assets excluding liquidity, reflects the real price of 22nd Century Group (XXII), which remains stable due to the absence of external geopolitical risks and the company's exclusive focus on the US domestic market.